Try our beta test site
8 studies found for:    Lymphoma OR CLL | Atezolizumab
Show Display Options
Rank Status Study
1 Recruiting Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Atezolizumab
2 Recruiting A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Condition: Lymphoma, Follicular
Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ];   Drug: Lenalidomide;   Drug: Obinutuzumab
3 Recruiting A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Atezolizumab;   Drug: Obinutuzumab;   Drug: Tazemetostat
4 Recruiting A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Lymphoma
Interventions: Drug: Atezolizumab [TECENTRIQ];   Drug: Obinutuzumab;   Drug: Polatuzumab Vedotin
5 Recruiting A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Refractory Diffuse Large B Cell Lymphoma
Interventions: Biological: KTE-C19;   Drug: atezolizumab (anti-PD-L1)
6 Recruiting A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
Interventions: Drug: Atezolizumab;   Drug: Bendamustine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Obinutuzumab;   Drug: Prednisone;   Drug: Vincristine;   Drug: Rituximab
7 Recruiting A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma
Conditions: Metastatic Cancer;   Solid Tumor;   Advanced Cancer;   NonHodgkin Lymphoma
Interventions: Drug: ALX148;   Drug: Atezolizumab;   Drug: Trastuzumab
8 Active, not recruiting A Phase 1 Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
Condition: Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Intervention: Drug: Atezolizumab

Study has passed its completion date and status has not been verified in more than two years.